Teva Sees Continued Legal Overhang As Q3 Sales Miss Mark
Firm Expects Branded Drugs To Drive Revenues Going Forward
Executive Summary
The company said it was optimistic about settling opioid litigation while still anticipating going to trial on price fixing.